Vascular Cognitive Impairment no Dementia Clinical Trial
— Cog-VACCINEOfficial title:
The Cog-VACCINE Study: a Randomized Controlled Clinical Trial to Evaluate the Effect of Cognitive Training in Patients With Vascular Cognitive Impairment, no Dementia
NCT number | NCT02640716 |
Other study ID # | 2015010 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2015 |
Est. completion date | December 2017 |
Verified date | July 2020 |
Source | Beijing Friendship Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the efficacy and mechanism of internet-based cognitive training in patients with subcortical VCIND. Half of participants will receive multi-domain adaptive internet-based training program, while the other half will receive a fixed, primary difficulty level task.
Status | Completed |
Enrollment | 60 |
Est. completion date | December 2017 |
Est. primary completion date | May 8, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - Literate Han Chinese, aged 50-78 years, with a consistent caregiver who accompanies the subject at least 4 days a week; - Complaint and/or informant report of cognitive impairment involving memory and/or other cognitive domains lasting for at least 3 months; - Neither normal nor demented according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, with a clinical dementia rating (CDR) = 0.5 on at least one domain and global score = 0.5; a Mini-Mental State Examination (MMSE) score = 20 (primary school) or = 24 (junior school or above); - Normal or slightly impaired activities of daily living as defined by a total score of = 1.5 on the three functional CDR domains (home and hobbies, community affairs, and personal care). The MRI entry criteria are as follows: - Multiple (= 3) supratentorial subcortical small infarcts (3-20 mm in diameter), with/without white matter lesions (WML) of any degree; or moderate to severe WML (score = 2 according to the Fazekas rating scale) with/without small infarct; - Absence of cortical and watershed infarcts, hemorrhages, hydrocephalus, and WMLs with specific causes (e.g., multiple sclerosis); - No hippocampal or entorhinal cortex atrophy (score 0 according to the medial temporal lobe atrophy scale of Scheltens). Exclusion Criteria: - severe aphasia, physical disabilities, or any other factor that may preclude completion of neuropsychological testing; - disorders other than subcortical VCIND that may affect cognition; - a Hamilton depression scale (HAMD) score >17 or schizophrenia; - new strokes within 3 months before baseline; - inherited or inflammatory small vessel disease; - clinically significant gastrointestinal, renal, hepatic, respiratory, infectious, endocrine, or cardiovascular system disease; - cancer, alcoholism, drug addiction; - use of medications that may affect cognitive functioning, including tranquilizers, anti-anxiolytics, hypnotics, nootropics, and cholinomimetic agents; - inability to undergo a brain MRI. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Friendship Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Friendship Hospital | Fu Xing Hospital, Capital Medical University, Xuanwu Hospital, Beijing |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Estimated Mean Change of MoCA | The participants will be followed up 6 months after recruitment. The training is not mandatory after 7 weeks, but the training details will be acquired from the online system. The change from baseline at month 6 in the MoCA difference is reported. The score of Moca ranges from 0 to 30, and higher scores mean a better outcome. |
Baseline and 6 months | |
Primary | Estimated Mean Change of the Montreal Cognitive Assessment (MoCA) | The study uses MoCA to assess changes in the global cognitive function after an intervention of cognitive training. Baseline and 7-week were the two relevant time points used in the calculation. The score of MoCA ranges from 0 to 30, and higher scores mean a better outcome. |
Baseline and 7 weeks | |
Primary | Estimated Mean Change of the Trail Making Test (TMT) B-A | The Trail Making Test is a commonly used neuropsychological test of visual attention and task-switching. In two timed tasks, subjects are asked to first connect numbers (Test A), then alternating numbers and letters (Test B), in sequential order as quickly as possible. Completion times, relating to cognitive processing speed and executive function (respectively) are represented as a difference (B-A). The Trail Making Test is a commonly used neuropsychological test of visual attention and task-switching. In two timed tasks, subjects are asked to first connect numbers (Test A), then alternating numbers and letters (Test B), in sequential order as quickly as possible. Completion times, relating to cognitive processing speed and executive function (respectively) are represented as a difference (B-A). The change from baseline at week 7 in the B-A difference is reported as a primar | Baseline and 7 weeks | |
Secondary | Estimated Mean Changes in Left Hippocampal Volume | The left hippocampal volume on structural Magnetic Resonance Imaging (MRI) was measured by voxel-based morphometrics. The estimated mean changes in left hippocampal volume from baseline at week 7 is reported. | Baseline and 7 weeks | |
Secondary | Estimated Mean Change in Right Hippocampal Volume | The right hippocampal volume on structural Magnetic Resonance Imaging (MRI) was measured by voxel-based morphometrics. The estimated mean change in right hippocampal volume from baseline at week 7 is reported. | Baseline and 7 weeks | |
Secondary | Estimated Mean Change in Brain White Matter Integrity | The white matter microstructure was measured by diffusion tensor imaging (DTI) . The whole-brain average fractional anisotropy (FA) was calculated to show brain white matter integrity. The change of whole-brain average FA from baseline at week 7 is reported. Fractional anisotropy (FA) is a scalar value between zero and one that describes the degree of anisotropy of a diffusion process. A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions. |
Baseline and 7 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02993367 -
The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND
|
Phase 2/Phase 3 | |
Completed |
NCT03306979 -
Memory and Antioxidants in Vascular Impairment Trial
|
Phase 2 |